Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

Case Report: A Patient Presents with Rare, Fulminant SAPHO Syndrome

Ross J. Thibodaux, MD, & Nirupa J. Patel, MD  |  October 18, 2018

Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a heterogeneous, inflammatory, musculoskeletal disease. The disease is an insidious, sterile osteitis with associated skin and synovial inflammation.1 Diagnosis can prove challenging, but a thorough clinical history, high clinical suspicion and imaging techniques can help clinch it. The below case reveals a rare, fulminant presentation of…

Filed under:Conditions Tagged with:case reportSAPHO Syndrome

RISE Lifts Research: The 2018 Annual Meeting Features 6 New Studies Based on RISE Data

Susan Bernstein  |  October 3, 2018

Data from the ACR’s Rheumatology Informatics System for Effectiveness (RISE) were used by rheumatology researchers in a crop of new studies that will be presented at the 2018 ACR/ARHP Annual Meeting, Oct. 19–24 in Chicago. Six abstracts, including four oral and two poster presentations, were accepted for this year’s meeting. They explore topics ranging from…

Filed under:American College of RheumatologyEducation & TrainingProfessional Topics Tagged with:2018 ACR/ARHP Annual MeetingRheumatology Informatics System for Effectiveness (RISE) clinical data registryRISE data

TNFi Exposure in Utero

Arthritis & Rheumatology  |  September 26, 2018

Vinet et al. evaluated the risk of serious infections in children of women with RA exposed to TNFi’s in the gestational period compared with unexposed offspring of women with RA, as well as with children from the general population. Although the research did not demonstrate a marked excess risk for serious infections, the authors could not exclude a differential risk according to specific TNFi, with infliximab potentially resulting in a threefold increase in the risk of serious infections compared with other TNFi’s. More studies are needed…

Filed under:Drug UpdatesResearch Rheum Tagged with:Arthritis & RheumatologyinfantspregnancyResearchTNF inhibitors

Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection

Thomas R. Collins  |  September 20, 2018

AMSTERDAM—With new therapies coming into the marketplace, researchers are working to tease out the risk of infection for rheumatoid arthritis (RA) patients. Existing data suggest the risk of infections—even fatal ones—is real. But over time, improvements have taken hold, particularly for tuberculosis, according to an infectious disease expert at EULAR: the Annual European Congress of…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:InfectionTuberculosis

Placebos: Their Underappreciated Impact in Pharmaceutical Trials

Placebos: Their Underappreciated Impact in Pharmaceutical Trials

Terence W. Starz, MD, Theodore Pincus, MD, On Behalf Of The ARHP Practice Committee  |  September 20, 2018

Sir William Osler, the father of modern medicine, said “the desire to take medicine is perhaps the greatest feature that separates man from animal.” Determination of the benefit of a medication can be challenging and includes a number of factors, such as pharmacologic activities on the disease pathophysiology, pharmacokinetic properties and patient characteristics.1,2 An additional,…

Filed under:Drug Updates Tagged with:clinical trialsplacebo

Immune Checkpoint Inhibitors & Immune-Related Adverse Events

Priya Chokshi, MD, Roberta Seidman, MD, Noah Levit, PhD, MD, & Steven E. Carsons, MD  |  September 20, 2018

Immune checkpoint inhibitors (ICIs) are at the forefront of advances in cancer therapy and have shown promising results for progression-free survival. Checkpoint signaling pathways, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), normally regulate the immune response to promote self-tolerance and prevent tissue damage and inflammation. PD-1 is a…

Filed under:ConditionsDrug UpdatesMyositisOther Rheumatic Conditions Tagged with:immune-related adverse eventsirAEsmyositisnivolumab

Case Report: A Psoriatic Arthritis Patient with Dactylitis & Enthesitis

Samantha C. Shapiro, MD; Jemima Albayda, MD; & Ana-Maria Orbai, MD, MHS  |  September 20, 2018

A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…

Filed under:ConditionsOther Rheumatic ConditionsPsoriatic Arthritis Tagged with:DactylitisEnthesitisPsAPsoriatic Arthritis

Investigators Assess Infection Risk with RA Biologics

Thomas R. Collins  |  August 29, 2018

Due to a range of factors, determining the precise infection risk posed by new biologic therapies to RA patients is difficult. But progress has been made and health registries may be helpful, said Olivier Lortholary, MD, PhD, during the 2018 EULAR: Annual European Congress of Rheumatology…

Filed under:Biologics/DMARDsDrug UpdatesEULAR/OtherMeeting Reports Tagged with:biologic drugsEULARInfectionRheumatoid Arthritis (RA)

Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches

Thomas R. Collins  |  August 17, 2018

AMSTERDAM—As more biosimilar drugs for rheumatic diseases make their way to market, evidence is growing that switching from the originator drug to a biosimilar tends to be effective, while the questions of switching back and forth, and switching multiple times using several different biosimilars, remain to be answered, an expert on the topic said at…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabbiosimilar substitutionsEnbreletanerceptHumiraINFLECTRA (infliximabdyyb)REMICADE (infliximab)Rituxanrituximab

Study Finds Tocilizumab Could Be Treatment Option for Takayasu Arteritis

Carina Stanton  |  August 17, 2018

For patients with refractory Takayasu arteritis (TAK), glucocorticoids (GCs) are often provided as the initial therapy for treatment. However, GCs are often associated with adverse effects for long-term use; relapse also occurs frequently during GC tapering.1 TAK involves interleukin (IL) 6. Tocilizumab—a recombinant, humanized, anti-IL-6 receptor (IL-6R) monoclonal antibody—was first reported by Nishimoto et al….

Filed under:ConditionsVasculitis Tagged with:ActemraTakayasu arteritis (TAK)tocilizumab

  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences